Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

IMPORTANCE: Patients with recurrent ovarian carcinoma frequently develop resistance to platinum-based chemotherapy, at which time treatment options become limited. OBJECTIVE: To evaluate the poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitor niraparib combined with pembrolizumab in patie...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:JAMA Oncol
Main Authors: Konstantinopoulos, Panagiotis A., Waggoner, Steven, Vidal, Gregory A., Mita, Monica, Moroney, John W., Holloway, Robert, Van Le, Linda, Sachdev, Jasgit C., Chapman-Davis, Eloise, Colon-Otero, Gerardo, Penson, Richard T., Matulonis, Ursula A., Kim, Young Bae, Moore, Kathleen N., Swisher, Elizabeth M., Färkkilä, Anniina, D’Andrea, Alan, Stringer-Reasor, Erica, Wang, Jing, Buerstatte, Nathan, Arora, Sujata, Graham, Julie R., Bobilev, Dmitri, Dezube, Bruce J., Munster, Pamela
Formato: Artigo
Idioma:Inglês
Publicado: American Medical Association 2019
Assuntos:
Original Investigation
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6567832/
https://ncbi.nlm.nih.gov/pubmed/31194228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.1048
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares